Document Detail


Noninvasive imaging of lipid nanoparticle-mediated systemic delivery of small-interfering RNA to the liver.
MedLine Citation:
PMID:  20628357     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Mouse models with liver-specific expression of firefly luciferase were developed that enable a noninvasive and longitudinal assessment of small-interfering RNA (siRNA)-mediated gene silencing in hepatocytes of live animals via bioluminescence imaging. Using these models, a set of lipid nanoparticles (LNPs) with different compositions of cationic lipids, polyethylene glycol (PEG), and cholesterol, were tested for their abilities in delivering a luciferase siRNA to the liver via systemic administration. A dose-dependent luciferase knockdown by LNP/siRNA assemblies was measured by in vivo bioluminescence imaging, which correlated well with the results from parallel ex vivo analyses of luciferase mRNA and protein levels in the liver. RNA interference (RNAi)-mediated target silencing was further confirmed by the detection of RNAi-specific target mRNA cleavage. A single dose of LNP02L at 3 mg/kg (siRNA) caused 90% reduction of luciferase expression and the target repression lasted for at least 10 days. With identical components, LNPs containing 2% PEG are more potent than those with 5.4% PEG. Our results demonstrate that these liver-luciferase mouse models provide a powerful tool for a high-throughput evaluation of hepatic delivery platforms by noninvasive imaging and that the molar ratio of PEG lipid can affect the efficacy of LNPs in silencing liver targets via systemic administration.
Authors:
Weikang Tao; Joseph P Davide; Mingmei Cai; Guo-Jun Zhang; Victoria J South; Andrea Matter; Bruce Ng; Ye Zhang; Laura Sepp-Lorenzino
Related Documents :
19447067 - Noninvasive structural, functional, and molecular imaging in drug development.
19362147 - Molecular imaging of prostate cancer.
12426227 - In vivo imaging of thrombin activity in experimental thrombi with thrombin-sensitive ne...
10096887 - Noncontact dipole effects on channel permeation. ii. trp conformations and dipole poten...
14745527 - Positron emission tomography in pediatric radiation oncology: integration in the treatm...
18066437 - Analysis of tectonic-controlled fluvial morphology and sedimentary processes of the wes...
Publication Detail:
Type:  Journal Article     Date:  2010-07-13
Journal Detail:
Title:  Molecular therapy : the journal of the American Society of Gene Therapy     Volume:  18     ISSN:  1525-0024     ISO Abbreviation:  Mol. Ther.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-02     Completed Date:  2010-12-22     Revised Date:  2011-09-13    
Medline Journal Info:
Nlm Unique ID:  100890581     Medline TA:  Mol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1657-66     Citation Subset:  IM    
Affiliation:
Department of RNA Therapeutics, Merck Research Laboratories, West Point, Pennsylvania 19486, USA. weikang_tao@merck.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Fluorescent Antibody Technique
Gene Silencing / physiology
Lipids / chemistry*
Liver / enzymology,  metabolism*
Luciferases / genetics
Mice
Nanoparticles / administration & dosage*,  chemistry*
RNA, Small Interfering / administration & dosage*,  genetics*
Chemical
Reg. No./Substance:
0/Lipids; 0/RNA, Small Interfering; EC 1.13.12.-/Luciferases
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Telomere capping in non-dividing yeast cells requires Yku and Rap1.
Next Document:  A short pulse of IL-4 delivered by DCs electroporated with modified mRNA can both prevent and treat ...